Concomitant use of atogepant, ubrogepant for migraine safe over 12 weeks
DENVER — The concomitant use of atogepant for preventive and ubrogepant for acute migraine treatment was found to be safe and well-tolerated over 12 weeks, according to research presented at the American Academy of Neurology annual meeting.Patients often take atogepant for prevention of migraine plus ubrogepant for acute treatment, Jessica Ailani, MD, director of the MedStar Georgetown